【摘要】 肠道微生物群及其代谢产物在调节宿主骨骼肌质量和功能方面发挥重要作用，为肠道微生物-肌肉轴的存在提供了有力支持。杜氏肌营养不良症（Duchenne muscular dystrophy,DMD）是一种快速进展、高致死率的遗传性肌肉疾病，长期激素治疗（如泼尼松和地夫可特等）是目前延缓DMD疾病进展的主要手段。DMD模型动物存在肠道微生物群失调和代谢产物改变，表现为整体微生物丰度显著降低，普雷沃菌属富集。恢复或改变肠道微生物群可改善DMD模型动物的肌肉病理表型。此外，长期使用糖皮质激素也会影响肠道微生物群的组成和多样性。与泼尼松相比，地夫可特可能对肠道微生物群的调节产生更有利的影响，后续需开展更多的临床研究来进一步验证。本综述聚焦于DMD患者肠道微生物群的特征性改变与全身性炎症、肌肉损伤及长期激素治疗影响的潜在关联，评估肠道微生物群作为潜在治疗靶点的可行性和有效性，为DMD的治疗提供新的思路和治疗策略。更多还原

【Abstract】 Gut microbiota and its metabolites play significant roles in regulating host skeletal muscle mass and function,providing strong support for the existence of the Gut microbiota-muscle axis. Duchenne muscular dystrophy(DMD) is a rapidly progressive, lethal genetic muscle disorder. Long-term glucocorticoid therapy(such as Prednisone and Deflazacort)remains the main treatment to slow down the disease progression. Animal studies demonstrate that DMD animal models exhibits gut dysbiosis and altered metabolite profiles, characterized by a significant reduction in overall microbial abundance and enrichment of Prevotella. Restoring or adjusting gut microbiota improves muscle pathology phenotype in DMD animal models. Furthermore, long-term glucocorticoid use can influence the composition and diversity of gut microbiota. Compared to Prednisone, Deflazacort may exert a more favorable impact on gut microbiota modulation. Future clinical studies are warranted to further validate these findings. This review focuses on the potential associations of the characteristic alterations of gut microbiota in DMD with systemic inflammation, muscle damage, and the effects of longterm glucocorticoid treatment. It aims to evaluate the feasibility and effectiveness of targeting gut microbiota as a potential therapeutic strategy, thereby providing new insights and treatment approaches for DMD.更多还原